{"id":123296,"date":"2017-10-12T05:01:00","date_gmt":"2017-10-12T09:01:00","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=123296"},"modified":"2017-10-12T05:01:00","modified_gmt":"2017-10-12T09:01:00","slug":"experimental-ebola-vaccines-induce-year-long-immune-response-in-trial","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2017\/10\/12\/experimental-ebola-vaccines-induce-year-long-immune-response-in-trial\/","title":{"rendered":"Experimental Ebola vaccines induce year-long immune response in trial"},"content":{"rendered":"
\"shutterstock\"<\/a>
Three groups of 500 volunteers received one of the experimental vaccines or a placebo (Shutterstock photo)<\/figcaption><\/figure>\n

WASHINGTON<\/strong>\u00a0— Two experimental Ebola vaccines can safely elicit immune responses by one month after initial vaccination that last for at least one year, results from a large clinical trial in Liberia showed Wednesday.<\/p>\n

The trial, published in the New England Journal of Medicine and conducted by a US-Liberia clinical research collaboration, involved 1,500 healthy adults who were rapidly enrolled at Redemption Hospital in Monrovia, capital of Liberia, in early 2015 during the West Africa Ebola outbreak.<\/p>\n

Three groups of 500 volunteers received one of the experimental vaccines or a placebo, and they all provided blood samples before vaccination and again at one week, one month, six months and one year post-vaccination.<\/p>\n

The vaccines included cAd3-EBOZ, co-developed by the US National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline; and rVSV-ZEBOV, which was initially engineered by scientists from the Public Health Agency of Canada and is now licensed to Merck Sharp & Dohme Corp., a subsidiary of Merck.<\/p>\n

Blood sample testing showed that responses at one week were modest with both vaccines but 71 percent of cAd3-EBOZ recipients and 84 percent of rVSV-ZEBOV recipients developed an antibody response by one month.<\/p>\n

At one year, 64 percent of cAd3-EBOZ recipients and 80 percent of rVSV-ZEBOV recipients still had an antibody response, indicating that antibody responses were largely maintained in both groups.<\/p>\n

Some participants who received the experimental vaccines experienced mild to moderate side effects, such as headache, muscle pain, feverishness and fatigue.<\/p>\n

Overall, the experiment did not identify any major safety concerns related to the vaccines. Most of the serious medical issues reported during the trial were due to malaria.<\/p>\n

“This clinical trial has yielded valuable information that is essential for the continued development of these two Ebola vaccine candidates and also demonstrates that well-designed, ethically sound clinical research can be conducted during an epidemic,” Anthony Fauci, director of the NIAID, which sponsored the trial, said in a statement.<\/p>\n

“A safe and effective vaccine would be a critically important addition to classical public health measures in controlling inevitable future Ebola outbreaks,” Fauci said.<\/p>\n

The Ebola virus disease is a severe, often fatal illness in humans. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. Currently, no Ebola vaccine has been licensed for use in humans.<\/p>\n","protected":false},"excerpt":{"rendered":"

WASHINGTON\u00a0— Two experimental Ebola vaccines can safely elicit immune responses by one month after initial vaccination that last for at …<\/p>\n","protected":false},"author":33,"featured_media":41340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[27427,1307,27431,1508,27430,27426,27428,27429],"class_list":["post-123296","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-cad3-eboz","tag-ebola","tag-experimental-vaccine","tag-liberia","tag-merck-sharp-dohme-corp","tag-new-england-journal-of-medicine","tag-rvsv-zebov","tag-us-national-institute-of-allergy-and-infectious-diseases","mauthors-xinhua","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/123296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=123296"}],"version-history":[{"count":0,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/123296\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/41340"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=123296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=123296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=123296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}